Loading...
 

Ποιστοποιητικο Αναλυσης ECOpure

http://www.intellicig.com/images/pdf/ECOpureReport2009-04-14.pdf

Dr Steven Rossington, Room 302, Centre for Molecular Drug Design, Cockcroft Building, The University of Salford, M5 4WT.

Tel: 0161 295 3861. Email: s.b.rossington@salford.ac.uk

 

 

Mr C Lord B.Eng Hons

Director

Intellicig Electronic Cigarette

Fort Street

Accrington

Lancashire

BB5 1QG

19th August 2009

 

Subject: Evaluation of Intellicig electronic cigarette – (ECOpure Regular - Medium Strength Cartridge)

Background: To establish the position of the Intellicig electronic cigarette in the light of recent reports regarding various other electronic cigarettes. More specifically this is in regards to establishing whether small molecules are present in either the cartridge liquid or indeed the inhaled ‘smoke form’ which could be potentially undesirable to the user.

The Food and Drug Administration (FDA) of the Department of Health and Human Services of the United States Government recently reported a scripture relating to the evolution of tobacco impurities such as Ethylene Glycol (EG), Diethylene Glycol (DEG) and Tobacco Specific Nitrosamines (TSNA) which are supposedly emitted in micro quantities upon vaporisation of similar electronic cigarette products available in the United States.(1)

 

Test Products:

Intellicig electronic cigarette (ECOpure Regular - Medium Strength Cartridge)

 

Conclusion:

The vaporised sample was achieved using a sparging apparatus (see picture below) using solvent conditions of water, acetonitrile phosphoric acid (800ml, 100ml, 11ml – 50ml of this solution) and pure acetonitrile. Over a ten minute period, 10 x 100ml of vapour was withdrawn and mixed with the solvent with each 100ml withdrawn over a period of 10 seconds. After 10 x 100ml samples a further 10 minutes mixing were allowed before samples were analysed by NMR, GCMS, and LCMS.

1H NMR spectroscopy, GCMS and LCMS was used to analyse the cartridge and also vaporised cigarette. Nicotine was shown to be present in all three forms of analysis along with glycerol. The 1H NMR spectroscopy performed under solvent suppressed conditions revealed that the vaporised sample showed to contain only glycerol and nicotine in their pure unaltered molecular form. An aliquot (0.5ml) of these vaporised solutions was dissolved in deuterated acetonitrile and the NMR’s were collected over an eight hour period. No other molecules apart from glycerol and nicotine were observed using a MESTREC NMR programme. This procedure was repeated using deuterated water as the NMR solvent with the same results as deuterated acetonitrile being observed. Since no other molecules representing possible impurities were present in the NMR it was deemed unnecessary to perform quantitive HS-GCMS analysis on the sample.

GCMS of the vaporised sample using the acetonitrile solvent in this sparging apparatus was also analysed under the conditions stated (see below ‘conditions of column’) The spectra revealed the presence of glycerol and nicotine and specifically did not show any indication on the MS of the reported TSNA impurities as observed by the referenced FDA publication. Likewise with GCMS the vaporised sample showed traces of glycerol in the MS but did not reveal any acrolein or the potential for EG / DEG.

 

LCMS of the vaporised cartridge showed that nicotine was present in its molecular form but did not give any indications of possible TSNA contaminants. For both GCMS and LCMS analysis a qualitative approach rather than a quantitative approach has been employed at this stage but further work in this area will include HS-GCMS and HPLC-UV analysis for the determination of nicotine and glycerol concentrations per 100ml ‘inhaled’ sample.

 

Conditions of Nuclear Magnetic Resonance

400 MHz Avance NMR Machine

Solvent of samples: Deuterated acetonitrile (CD3CN), deuterated water (D2O).

 

Conditions of Liquid Chromatography Mass Spectrometry

Column: DB5-MS 30m 0.25 i.d. 0.25um (micro metre) film

Carrier Flow: 1.0 ml/min

Injection Volume: 0.2 ul (microlitre) split ratio of 100:1

Injection temp: 300oC

GC Programme: 50oC, 1.0 min hold, 10oC/min to 300oC, hold 10 mins.

 

Conditions of Gas Chromatography Mass Spectrometry

As per LCMS above.

 

 

GCMS

NMR

LCMS

 

 

 

 

Tobacco Specific Nitrosamines

NAB

Not Detected

Not Detected

Not Detected

NAT

Not Detected

Not Detected

Not Detected

NNK

Not Detected

Not Detected

Not Detected

NNN

Not Detected

Not Detected

Not Detected

 

 

 

 

Glycerol  VG

Detected

Detected

Detected

Nicotine

Countries

applicable only

Detected

Detected

Detected

 

 

 

 

Diethylene Glycol

Not Detected

Not Detected

Not Detected

Ethylene Glycol

Not Detected

Not Detected

Not Detected

 

Tobacco Specific impurities

Cotinine

Not Detected

Not Detected

Not Detected

Anabasine

Not Detected

Not Detected

Not Detected

Myosmine

Not Detected

Not Detected

Not Detected

β-nicotyrine

Not Detected

Not Detected

Not Detected

 

 

 

 

NAB=N-nitrosoanabasine, NAT=N-nitrosoanatabine, NNK=4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, NNN=N-nitrosonornicotine These are potential tobacco specific impurities identified by the FDA.(1) 

NMR detection limit- 50 nmol. GCMS detection limit-100 nmol

 

 

 

Δεν υπάρχουν προϊόντα Κάτω από αυτήν την Κατηγορία.